AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03335488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaPBA
Description: * NaPBA in patients weighing \< 20 Kg - 600 mg/Kg, maximum total daily dose~* NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose
Study NCT00739440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serum antiscorpion
Description: The dose may be required for the patient according to clinical manifestations and evolution
Study NCT03484052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Jugular ultrasound
Description: Performing a jugular ultrasound by 2 operators before and after transfusion
Study NCT00498927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00498927 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT00498927 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00498927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study NCT00498927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT02303730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose\<2.9 mmol/l or \< 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
Study NCT02303730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c \<8% use 0.1 -0.2 U/kg per day;HbA1c >8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) > 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose \<70mg/dl（3.9mmol/l）: 10%-20%; blood glucose \<40mg/dl（2.2mmol/l）: 20%-40%.
Study NCT02183792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Study NCT02183792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Study NCT03093974 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 ml saline solution 0.45%. the placebo was made up of identical empty glass vials to which the same saline diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to maintain the blind.
Study NCT01486992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRI+Nimotuzumab
Description: irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
Study NCT01852591 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV 13
Study NCT02030457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI
Description: Breath Activated Inhaler (BAI)
Study NCT03672032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fork-tip Needle
Description: Fork-tip Needle will be used to obtain biopsy
Study NCT03672032 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Franseen Needle
Description: Franseen Needle will be used to obtain biopsy
Study NCT01078272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
Study NCT01078272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Remote Ischemic Preconditioning
Description: Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
Study NCT03223688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day-Care early intervention program
Description: The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
Study NCT03223688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPD+SI intervention program
Description: The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
Study NCT03223688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OPD intervention program
Description: The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
Study NCT03696056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation
Description: The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
Study NCT03696056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music listening program
Description: The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log.
Study NCT05247307 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: convalescent plasma infusion covid 19
Description: Operating process~* A single dose of plasma (300 mL) immune anti-coronavirus or not, depending on what corresponds will be infused.~* The collaborating staff will enter the initial and follow-up data in Red Cap based on the information contained in the medical record, or by talking to the patient by telephone to clarify any doubts.
Study NCT05247307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: convalescent plasma infusion covid 19
Description: Operating process~* A single dose of plasma (300 mL) immune anti-coronavirus or not, depending on what corresponds will be infused.~* The collaborating staff will enter the initial and follow-up data in Red Cap based on the information contained in the medical record, or by talking to the patient by telephone to clarify any doubts.
Study NCT01064609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy by cryoprobes
Description: Transbronchial lung biopsy with cryoprobes.
Study NCT02085525 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nurse Practitioner Clinic
Description: The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs.
Study NCT03407378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPT803
Description: Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
Study NCT03407378 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Optional pharmacogenetic assessment
Description: Blood sample of 3 milliliters for genotyping assessment (according to patient consent).
Study NCT03407378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)
Study NCT03407378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optional Blood-Oxygen-level Dependent functionalMRI
Description: BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)
Study NCT03407378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Assessments before taking regular PD treatment
Description: Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.
Study NCT03407378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Assessments on regular PD treatment
Description: Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
Study NCT00421538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nadroparine calcium
Description: Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
Study NCT00421538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
Study NCT02606435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention (PCI)
Description: percutaneous coronary intervention (PCI) by stent implantation
Study NCT02606435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention (PCI)
Description: percutaneous coronary intervention (PCI) by stent implantation
Study NCT02030457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate MDI
Description: Metered Dose Inhaler (MDI)
Study NCT04337203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARE-S Implementation Program
Description: The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).
Study NCT04737551 — intervention group
Intervention type: OTHER
Intervention: Follow-up only
Description: Only routine follow-up but no treatment
Study NCT04737551 — intervention group
Intervention type: DRUG
Intervention: Adjuvant chemotherapy
Description: Chemotherapy regimens will be decided by physicians or MDT teams, basing on patients' physical status, income status, and/or desire. Toxicity was evaluated every cycle and efficacy was evaluated every two cycles. The treatment course of adjuvant chemotherapy was followed the recommendation of NCCN guideline.
Study NCT04737551 — intervention group
Intervention type: RADIATION
Intervention: Adjuvant chemoradiotherapy
Description: Adjuvant CRT could be delivered before or simultaneously with adjuvant chemotherapy. Radiation used 6 MV or 15 MVX-ray beams delivering daily fractions of 180-200cGy to a total dose of 45-55Gy in 25-28 fractions using CT-based, three-dimensional conformal radiation therapy (3DRT), intensity-modulated radiation therapy (IMRT) or tomotherapy (TOMO).~S-1 was administered orally at a dose of 40mg twice a day during radiation day as radiosensitizer through radiotherapy. Antiemetic medications and proton pump inhibitor were prophylactic used to reduce the occurrence of nausea and inhibit gastric acid secretion.
Study NCT02606435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thrombus aspiration
Description: thrombus aspiration with export catheter
Study NCT04333940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periapical surgery
Description: clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
Study NCT04333940 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periapical surgery
Description: clinical signs and symptoms, probing depth, Clinical attachment level (CAL ), dimensions of lesion, distance from the defect and apex of tooth to the anatomical structures will be measured
Study NCT06416176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) Program
Description: Participants in the experimental group received an 8-week MBSR program by an MBSR instructor. Each meeting were planned as a 3-hour session that completes the mindfulness training procedures by doing an opening meditation of 30- 45 minutes about that week, after the information about the meeting topic of the week is discussed. Experiences after meditation were shared with the group. Each week, the meeting topic and meditation continued with different contents, and practice meditations on the subject were held every week and home exercises were given. Home practice meditations were performed by listening to the guide audio recording with headphones. All home exercises in the training content were followed up on a daily basis and recorded.
Study NCT03109262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: As part of PET/CT and SPECT/CT scans.
Study NCT03109262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: As part of PET/CT scan
Study NCT03109262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 90-Yttrium (Y-90) Glass Microspheres
Description: Radiolabel for PET/CT scan
Study NCT01724086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
Study NCT03109262 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Technetium 99mTc albumin aggregated (99mTc-MAA)
Description: Radiolabel for 99mTc-MAA SPECT/CT Scan
Study NCT03109262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-photon emission computerized tomography (SPECT) scan
Description: As part of SPECT/CT scan
Study NCT02133664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipoic acid and omega-3 fatty acids
Description: alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
Study NCT02133664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lipoic acid and placebo oil
Study NCT03789695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
Study NCT03789695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate
Description: Study drug dabigatran etexilate. There are two dosage regimens of dabigatran etexilate used in the study: 150 mg b.i.d. and 110 mg b.i.d. The dose of dabigatran etexilate will be chosen by the investigator in accordance with Russian PRADAXA SmPC
Study NCT02815436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone reminder
Description: a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
Study NCT02815436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminder
Description: a one-way, SMS message sent from the centre to the screening participant's mobile phone
Study NCT00003787 — intervention group
Intervention type: BEHAVIORAL
Intervention: educational/counseling intervention
Study NCT00003787 — intervention group
Intervention type: BEHAVIORAL
Intervention: therapeutic dietary intervention
Study NCT04054492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-IPV+bOPV+bOPV
Description: 202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
Study NCT04054492 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin-IPV+Sabin-IPV+bOPV
Description: 197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
Study NCT04054492 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin-IPV+Sabin-IPV+Sabin-IPV
Description: 205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
Study NCT01724086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a (PegIFN)
Description: Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
Study NCT04737551 — intervention group
Intervention type: RADIATION
Intervention: Adjuvant chemoradiotherapy + Adjuvant chemotherapy
Description: See as above (adjuvant chemotherapy and adjuvant chemoradiotherapy).
Study NCT02194192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 10 ml
Study NCT02194192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondasetron 8 mg IV after spinal anesthesia
Study NCT02194192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Ephedrine 10 mg IV after spinal anesthesia
Study NCT01431456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: Dabigatran
Study NCT01431456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban
Study NCT01431456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: Nadroparin
Study NCT00989664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab
Description: Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation.
Study NCT03479203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette Aerosol
Description: 16 two-second-long puffs from a non-nicotinized electronic cigarette.
Study NCT03194672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Adolescent Transitions (HAT) program
Description: The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities.